MedTrace Logo

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

NCT05621317 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-10-15

No results posted yet for this study

Summary

The overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with peanut allergy.

Conditions

  • Peanut Allergy
  • Peanut Hypersensitivity
  • Peanut-Induced Anaphylaxis
  • Immune System Diseases

Interventions

BIOLOGICAL

PVX-108

PVX108 comprises a mixture of peptides that represent sequences from peanut allergens

BIOLOGICAL

Placebo

Matching placebo comprises the formulation vehicle without peptides

Sponsors & Collaborators

  • Aravax Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Brian Vickery, MD · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-09
Primary Completion
2025-11-30
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05621317 on ClinicalTrials.gov